Free tool
FAERS Monitor: Janumet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022044 or its brand name (Janumet, Metformin Hydrochloride, Sitagliptin Phosphate). Reports on generic versions are filed under their own applications.
Reports
19,518
Serious
13,277
68% of reports
Hospitalization
6,718
Death reported
2,052
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,318
- diarrhoea1,214
- nausea1,004
- drug ineffective886
- acute kidney injury823
- fatigue821
- vomiting706
- weight decreased671
- dyspnoea581
- pancreatic carcinoma575
- pancreatitis575
- dizziness573
- death569
- lactic acidosis559
- off label use559
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 39 |
| 2008 | 131 |
| 2009 | 254 |
| 2010 | 384 |
| 2011 | 537 |
| 2012 | 839 |
| 2013 | 1,225 |
| 2014 | 1,686 |
| 2015 | 2,188 |
| 2016 | 1,897 |
| 2017 | 1,497 |
| 2018 | 1,634 |
| 2019 | 1,481 |
| 2020 | 1,378 |
| 2021 | 1,149 |
| 2022 | 909 |
| 2023 | 801 |
| 2024 | 664 |
| 2025 | 505 |
| 2026 | 320 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,641 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancreatic carcinomaSignal | 575 | 21.9 | 20.2 | 11,219 |
| lactic acidosisSignal | 559 | 18.9 | 17.4 | 9,314 |
| pancreatitisSignal | 575 | 11.8 | 10.9 | 5,650 |
| blood glucose increasedSignal | 1,318 | 7.6 | 7.2 | 7,542 |
| acute kidney injurySignal | 823 | 5.8 | 5.4 | 3,288 |
| weight decreasedSignal | 671 | 2.6 | 2.4 | 663 |
| diarrhoeaSignal | 1,214 | 2.0 | 1.9 | 651 |
| vomiting | 706 | 1.6 | 1.5 | 170 |
| nausea | 1,004 | 1.4 | 1.3 | 103 |
| dizziness | 573 | 1.2 | 1.1 | 27 |
| fatigue | 821 | 1.1 | 1.1 | 14 |
| dyspnoea | 581 | 1.1 | 1.0 | 6 |
| drug ineffective | 886 | 0.7 | 0.7 | 99 |
| death | 569 | 0.7 | 0.7 | 69 |
| off label use | 559 | 0.7 | 0.6 | 82 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.